HuM&C's reported results peaked in 2023 and then declined in 2024 and 2025. Revenue rose from KRW 35.6 billion in 2022 to KRW 48.4 billion in 2023 (up 35.9% year on year), eased to KRW 47.2 billion in 2024 (down 2.5%), and reached KRW 52.3 billion in 2025 (up 10.8%), the largest year in the 2022 to 2025 window.
Operating profit went from KRW 1.77 billion in 2022 to KRW 4.84 billion in 2023 (up 174.1%) and KRW 4.95 billion in 2024 (up 2.2%), then fell to KRW 2.48 billion in 2025 (down 49.8%).
The operating margin moved from 5.0% in 2022 to 10.0% in 2023 and 10.5% in 2024 before dropping to 4.7% in 2025, so the margin fell in the year revenue grew most.
Net profit attributable to controlling shareholders rose from KRW 798 million in 2022 to KRW 10.3 billion in 2023 (up 1,191.3%), the peak, then fell to KRW 3.4 billion in 2024 (down 67.0%) and KRW 1.57 billion in 2025 (down 53.8%), declining for two consecutive years from 2024 to 2025.
Net profit including non-controlling interests was reported at the same amounts in each of those years. Net profit in 2023 well exceeded operating profit of KRW 4.84 billion, which points to non-operating items that the next annual report's income statement should clarify.
At the end of 2025, total equity was KRW 45.5 billion, all of it attributable to controlling shareholders, total liabilities were KRW 16.3 billion, and the debt ratio was 35.8%. Operating cash flow was KRW 2.07 billion in 2022, KRW 6.14 billion in 2023, KRW 4.91 billion in 2024 and KRW 4.96 billion in 2025.
On a quarterly basis, Q3 2025 revenue was KRW 13.4 billion with operating profit of KRW 730 million, and Q4 2025 revenue of KRW 13 billion (down 2.9% quarter on quarter) with operating profit of KRW 464 million (down 36.3%) marked the low point.
Q1 2026 revenue was KRW 14.5 billion with operating profit of KRW 823 million (up 77.2%), and Q2 2026 revenue was KRW 15.7 billion with operating profit of KRW 1.24 billion, the highest quarterly operating profit in the reported window.
Q3 2026 revenue was KRW 15 billion (down 4.4% quarter on quarter, up 11.9% year on year) and operating profit was KRW 1.02 billion (down 18.0% quarter on quarter, up 39.8% year on year).
Net profit attributable to controlling shareholders was KRW 94.17 million, down 90.4% quarter on quarter and 85.8% year on year, which the company attributed to foreign-currency translation losses as the won weakened.
Over the last four reported quarters, net profit attributable to controlling shareholders totaled KRW 2.62 billion. The company described Q1 2026 as its best quarterly result on record, citing better cost ratios, demand for vials used in health functional foods, and the start of Vietnam production.